Dextrometorfano* e seus sais
ANVISA lists this substance among materials that may not be used in personal-hygiene products, cosmetics or perfumes in Brazil.
Regulatorische Entscheidung und vollständige Bedingungen
- Status
- Prohibited
- Rechtsrolle
- Binding rule
- Regulatorische Zusammenfassung
- ANVISA lists this substance among materials that may not be used in personal-hygiene products, cosmetics or perfumes in Brazil.
- Bedingungen und Beschränkungen
Dextrometorfano* e seus sais
Stoffidentität
- Name in der amtlichen Quelle
- Dextrometorfano* e seus sais
- CAS
- 125-71-3
- EC
- 204-752-2
- Identitätszuordnung
- standalone:official_anvisa_record
Marktübergreifende Übersicht zu dieser Identität
Exakte verknüpfte Einträge, die derzeit auf dieser Website vorhanden sind. Ein fehlender Markt bedeutet, dass kein exakter Treffer importiert wurde, nicht dass der Stoff verwendet werden darf.
European Union
1 verknüpfter Eintrag
Unterstützenden Eintrag öffnenGreat Britain
1 verknüpfter Eintrag
Unterstützenden Eintrag öffnenCanada
1 verknüpfter Eintrag
Unterstützenden Eintrag öffnenNew Zealand
1 verknüpfter Eintrag
Unterstützenden Eintrag öffnenASEAN
1 verknüpfter Eintrag
Unterstützenden Eintrag öffnenChina
1 verknüpfter Eintrag · 1 mit besonderen Bedingungen
Unterstützenden Eintrag öffnenSouth Korea
1 verknüpfter Eintrag · 1 mit besonderen Bedingungen
Unterstützenden Eintrag öffnenBrazil
Aktueller Eintrag1 verknüpfter Eintrag · 1 mit besonderen Bedingungen
Unterstützenden Eintrag öffnenIndia
1 verknüpfter Eintrag · 1 mit besonderen Bedingungen
Unterstützenden Eintrag öffnenSaudi Arabia
1 verknüpfter Eintrag
Unterstützenden Eintrag öffnen
Verifizierte Chemie für CAS 125-71-3
Dextromethorphan
Dextromethorphan is a 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene in which the sterocenters at positions 4a, 10 and 10a have S-configuration. It is a prodrug of dextrorphan and used as an antitussive drug for suppressing cough. It has a role as a oneirogen, a xenobiotic, a prodrug, a neurotoxin, an antitussive, a NMDA receptor antagonist and an environmental contaminant. It is functionally related to a dextrorphan. It is an enantiomer of a levomethorphan. — ChEBI
- IUPAC-Name
- (1S,9S,10S)-4-methoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene
- Summenformel
- C18H25NO
- Molekulargewicht
- 271.4 g/mol
- Exakte Masse
- 271.193614421 Da
- Monoisotopische Masse
- 271.193614421 Da
- XLogP3
- 3,4
- Topologische polare Oberfläche
- 12,5 Ų
- Molekulare Komplexität
- 370,0
- Formale Ladung
- 0
- Wasserstoffbrücken-Donoren
- 0
- Wasserstoffbrücken-Akzeptoren
- 2
- Drehbare Bindungen
- 1
- Schweratome
- 20
- Kovalente Einheiten
- 1
An PubChem gemeldete Namen und Synonyme
16 weitere gemeldete Namen
Kennungen in externen Datenbanken
- ChEBI:CHEBI:4470
- ChEBI:CHEBI:92579
- ChEMBL:CHEMBL52440
- EPA DTXSID:DTXSID3022908
- PubMed:22608604
- PubMed:22073096
- PubMed:22066053
- PubMed:22044595
- PubMed:21973086
- PubMed:21867562
- PubMed:21614312
- PubMed:21445282
- PubMed:21436715
- PubMed:21266064
- PubMed:21244712
- PubMed:21175434
Erweiterte Strukturstatistik
- Definierte Atom-Stereozentren
- 3
- Nicht definierte Atom-Stereozentren
- 0
- Definierte Bindungs-Stereozentren
- 0
- Nicht definierte Bindungs-Stereozentren
- 0
- 3D-Pharmakophormerkmale
- 6
- 3D-Ringe
- 4
- 3D-Hydrophobe
- 0
- 3D-Akzeptormerkmale
- 1
- 3D-Donormerkmale
- 0
- 3D-Anionenzentren
- 0
- 3D-Kationenzentren
- 1
- 3D-Konformere
- 2
- Effektive 3D-Rotoren
- 2,6
Maschinenlesbare Strukturkennungen
- SMILES
CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC- InChI
InChI=1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m1/s1- InChIKey
MKXZASYAUGDDCJ-NJAFHUGGSA-N
Belege aus weiteren wissenschaftlichen Datenbanken
NIH PubChem PUG-View
Attributed physical-property, hazard, environmental and use annotations.
- Color/Form: White to slightly yellow crystalline powder Quelle: Hazardous Substances Data Bank (HSDB)
- Melting Point: 122-124 Quelle: DrugBank
- Melting Point: 109-111 °C Quelle: Hazardous Substances Data Bank (HSDB)
- Odor: Odorless Quelle: Hazardous Substances Data Bank (HSDB)
- Solubility: 1.5 g/100 mL Quelle: DrugBank
- Solubility: Practically insoluble in water Quelle: Hazardous Substances Data Bank (HSDB)
- Solubility: Freely soluble in chloroform Quelle: Hazardous Substances Data Bank (HSDB)
- Carcinogen Classification: No indication of carcinogenicity to humans (not listed by IARC). Quelle: Toxin and Toxin Target Database (T3DB)
- Exposure Routes: Oral, rapidly absorbed from the gastrointestinal tract. Quelle: Toxin and Toxin Target Database (T3DB)
- Note: This chemical does not meet GHS hazard criteria for 46.8% (36 of 77) of reports. Quelle: European Chemicals Agency (ECHA)
- Signal: Danger Quelle: European Chemicals Agency (ECHA)
- GHS Hazard Statements: H301 (51.9%): Toxic if swallowed [Danger Acute toxicity, oral] Quelle: European Chemicals Agency (ECHA)
- Precautionary Statement Codes: P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement) Quelle: European Chemicals Agency (ECHA)
- ECHA C&L Notifications Summary: Aggregated GHS information provided per 77 reports by companies from 4 notifications to the ECHA C&L Inventory.; Reported as not meeting GHS hazard criteria per 36 of 77 reports by companies.; There are 3 notifications provided by 41 of 77 reports by companies with hazard statement code(s).; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. Quelle: European Chemicals Agency (ECHA)
- Health Effects: Hypertension, shallow respiration. Dextromethorphan can cause other gastrointestinal disturbances. [Wikipedia] Quelle: Toxin and Toxin Target Database (T3DB)
- Toxicity Summary: IDENTIFICATION AND USE: Dextromethorphan is a white odorless solid crystal or powder. It is an opium alkaloid derivative, which is found in cough and cold preparations. HUMAN STUDIES: Dextromethorphan is a drug of abuse. The main risks associated with dextromethorphan are ataxia, central nervous system (CNS) stimulation, dizziness, lethargy and psychotic behavior. Less frequently with large doses seizures and respiratory depression can occur. Nausea, vomiting, constipation and tachycardia may also occur. CNS effects include ataxia, drowsiness, vertigo and rarely coma. CNS stimulation may be observed. Restlessness, increased muscle tone with body rigidity have been reported. With extremely large ingestions respiratory depression can occur. Gastrointestinal effects include nausea, vomiting, constipation and dry mouth. Urinary retention may be seen. Dextromethorphan abuse has been described and produces euphoria, CNS stimulation, visual and/or auditory hallucinations. Dextromethorphan hydrobromide is the drug form, thus the possibility of bromide poisoning should be considered in the long term abuser. Dextromethorphan enhances serotonin activity by inhibiting the reuptake of serotonin Quelle: Hazardous Substances Data Bank (HSDB)
- Toxicity Summary: Signs and Symptoms of Overdose; One significant concern regarding dextromethorphan toxicity is its OTC misuse, which has steadily increased since the early 2000s. This misuse is referred to by slang terms such as "going pharming," "robotripping," and "dexing." In 2006, three specific OTC product formulations accounted for 66% of reported dextromethorphan misuse cases in the United States, with Coricidin HBP Cough & Cold Tablets and Robitussin products being prominent. A life-threatening toxicity associated with dextromethorphan abuse is serotonin syndrome, resulting from its serotonin reuptake inhibition properties. When combined with SSRIs or MAOIs, the risk of serotonin syndrome increases significantly. Symptoms include agitation, confusion, dilated pupils, headache, tachycardia, hypotension, high fever, seizures, irregular heartbeat, and may progress to unconsciousness.; Despite the rise in misuse, public health efforts and legislative actions restricting the sale of dextromethorphan-containing products to minors have helped stabilize or reduce abuse rates in recent years. However, continued vigilance is essential to prevent misuse and associated toxicities, given dextromethorph Quelle: StatPearls
- Toxicity Summary: Dextromethorphan is an opioid-like drug that binds to and acts as antagonist to the NMDA glutamatergic receptor, it is an agonist to the opioid sigma 1 and sigma 2 receptors, it is also an alpha3/beta4 nicotinic receptor antagonist and targets the serotonin reuptake pump. Dextromethorphan is rapidly absorbed from the gastrointestinal tract, where it enters the bloodstream and crosses the blood-brain barrier. The first-pass through the hepatic portal vein results in some of the drug being metabolized into an active metabolite of dextromethorphan, dextrorphan, the 3-hydroxy derivative of dextromethorphan. Quelle: Toxin and Toxin Target Database (T3DB)
- Environmental Bioconcentration: The estimated pKa of dextromethorphan is 9.8(1), indicating that dextromethorphan will exist almost entirely in the cation form at pH values of 5 to 9 and, therefore, bioconcentration in fish is not expected to be an important fate process(SRC). Quelle: Hazardous Substances Data Bank (HSDB)
- Environmental Fate: TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 23,000(SRC), determined from a structure estimation method(2), indicates that dextromethorphan is expected to be immobile in soil(SRC). The estimated pKa of dextromethorphan is 9.8(3), indicating that this compound will exist almost entirely in the cation form in the environment and cations generally adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(4). Volatilization of the cation from moist soil is not expected because cations do not volatilize(SRC). Dextromethorphan is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 1.0X10-5 mm Hg at 25 °C(SRC), determined from a fragment constant method(2). Biodegradation data in soil were not available(SRC, 2017). Quelle: Hazardous Substances Data Bank (HSDB)
- Environmental Fate: AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 23,000(SRC), determined from a structure estimation method(2), indicates that dextromethorphan is expected to adsorb to suspended solids and sediment(SRC). An estimated pKa of 9.8(3) indicates dextromethorphan will exist almost entirely in the cation form at pH values of 5 to 9 and, therefore, volatilization from water surfaces and bioconcentration in aquatic organisms are not expected to be an important fate processes(SRC). Dextromethorphan is not expected to undergo hydrolysis in the environment due to the lack of functional groups that hydrolyze under environmental conditions(4). Biodegradation data in water were not available(SRC, 2017). Quelle: Hazardous Substances Data Bank (HSDB)
- Environmental Fate: ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), dextromethorphan, which has an estimated vapor pressure of 1.0X10-5 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), will exist in both the vapor and particulate phases in the ambient atmosphere. Vapor-phase dextromethorphan is degraded in the atmosphere by reaction with photochemically-produced hydroxyl radicals(SRC); the half-life for this reaction in air is estimated to be 3.3 hours(SRC), calculated from its rate constant of 1.2X10-10 cu cm/molecule-sec at 25 °C(SRC) that was derived using a structure estimation method(2). Particulate-phase dextromethorphan may be removed from the air by wet or dry deposition(SRC). Dextromethorphan contains chromophores that absorb at wavelengths >290 nm(3) and, therefore, is expected to be susceptible to direct photolysis by sunlight(SRC). Quelle: Hazardous Substances Data Bank (HSDB)
- Uses: Antitussive Agents; Excitatory Amino Acid Antagonists Quelle: Hazardous Substances Data Bank (HSDB)
- Uses: Probe to determine cytochrome 450 phenotype Quelle: Hazardous Substances Data Bank (HSDB)
- Uses: MEDICATION Quelle: Hazardous Substances Data Bank (HSDB)
- Uses: Dextromethorphan (DXM) is an over-the-counter (OTC) cough suppressant commonly found in cold medications. DXM is often abused in high doses by adolescents to generate euphoria and visual and auditory hallucinations. Illicit use of DXM is referred to on the street as "Robo-tripping" or "skittling." These terms are derived from the most commonly abused products, Robitussin and Coricidin. Quelle: Hazardous Substances Data Bank (HSDB)
- Uses: Use (kg; approx.) in Germany (2009): >1000; Use (kg) in USA (2002): 38000; Consumption (g per capita; approx.) in Germany (2009): 0.0122; Consumption (g per capita) in the USA (2002): 0.135; Excretion rate: 0.25; Calculated removal (%): 45.3 Quelle: NORMAN Suspect List Exchange
- Uses: The primary use of dextromethorphan is as a cough suppressant, for the temporary relief of cough caused by minor throat and bronchial irritation (as commonly accompanies the common cold), as well as those resulting from inhaled irritants. In addition, a combination of dextromethorphan and quinidine has been shown to alleviate symptoms of easy laughing and crying (pseudobulbar affect) in patients with amyotrophic lateral sclerosis and multiple sclerosis. Quelle: Toxin and Toxin Target Database (T3DB)
Zugeordnet durch: Existing checksum-valid CAS to unique PubChem CID match. Abgerufen: 2026-08-31. Quelleneintrag öffnen
Wissenschaftliche Klassifizierungen und Gefahrenannotationen liefern Kontext und ersetzen nicht die oben gezeigte marktspezifische regulatorische Entscheidung.
Weitere Quellenabdeckung und Trefferstatus
| Quelle | Ergebnis | Geprüft |
|---|---|---|
| NIH PubChem PUG-View | Exakter Treffer | 2026-08-31 |
Ein erfasster Nicht-Treffer ist ein nützlicher Beleg dafür, dass die Quelle geprüft wurde; er ist keine Behauptung, dass der Stoff anderswo nicht existiert.
Am 2026-08-31 von NIH PubChem durch prüfsummengültigen CAS-Abgleich abgerufen. Chemische Eigenschaften ersetzen nicht die regulatorische Entscheidung auf dieser Seite.
Amtliche Quelle und Herkunft
- Registrierte Quelle
- Brazil ANVISA consolidated prohibited substances — RDC 529/2021 through RDC 1.030/2026
- Quellenverweis
- RDC 529/2021 consolidated annex, entry 226 (through RDC 1.030/2026)
- Eintrags-ID der Quelle
annex:226- Quellenversion
- RDC 529/2021 consolidated through RDC 1.030/2026
- Quellsprache
- Portuguese with official English identity where published
- Übersetzungsstatus
- Official English translation · Englische Übersetzung
- Datum des Inkrafttretens
- 2026-06-15
- Quelle aktualisiert
- 2026-06-15
- Stand geprüft
- 2026-08-31 15:26 UTC
- Validierungsmethode
- pdfplumber government baseline + 4 RDC 1.030 exclusions + 15 additions; 1,387 substantive rows
- SHA-256
a212e85540a186a842664fbdd4f351af0b1b4baeeb0c4765b9b52c6ce91c1e84
Hinweise zum registrierten Datensatz
- Datensatzabdeckung
- All 1,387 substantive current prohibited rows after applying RDC 1.030/2026 additions, amendments and exclusions to RDC 529/2021
- Hinweis zur Behörde
- Binding consolidated prohibited list for personal-hygiene products, cosmetics and perfumes
Wie dieser Eintrag in den Marktdatensatz passt
Statusverteilung
Bedingungstext ist bei 1387 von 1387 aktuellen Einträgen vorhanden. Ein leeres Bedingungsfeld wird entsprechend der oben genannten Eintragsart interpretiert; es wird niemals in die Aussage einer uneingeschränkten Verwendung umgedeutet.
Brazil Marktkontext
Complete prohibited dataset plus current restricted-list workflow
Abdeckungsversion: ANVISA RDC 1.029/2026 and RDC 1.030/2026, published 15 June 2026
All 1,387 substantive current prohibited rows in RDC 529/2021 consolidated through RDC 1.030/2026, plus the current RDC 1.029 restricted-list and identity workflow.
Verifizierungs-Checkliste
- Resolve Portuguese, INCI and CAS identity with the ANVISA crosswalk.
- Check the consolidated prohibited list including RDC 1.030/2026 changes.
- Apply RDC 1.029/2026 restrictions and the still-effective complementary rules.
- Verify Mercosur incorporation, regularisation, labelling and transition periods.
Amtliche Marktquellen
- Brazil ANVISA INCI translation panelIdentity and labelling crosswalk only; regulatory lists must be sourced separately
- Brazil ANVISA restricted substances — RDC 1.029/2026Binding ANVISA resolution effective on publication; replaced RDC 530/2021 for this list part
- Brazil ANVISA consolidated prohibited substances — RDC 529/2021 through RDC 1.030/2026Binding consolidated prohibited list for personal-hygiene products, cosmetics and perfumes
Verifizierungsablauf und Vollständigkeit des Eintrags
Bevor Sie dieses Ergebnis für eine Compliance-Entscheidung verwenden
- Bestätigen Sie, dass „Dextrometorfano* e seus sais“ und jede CAS-/EC-Kennung sich auf das Material in Ihrer Lieferantenspezifikation beziehen.
- Resolve Portuguese, INCI and CAS identity with the ANVISA crosswalk.
- Check the consolidated prohibited list including RDC 1.030/2026 changes.
- Apply RDC 1.029/2026 restrictions and the still-effective complementary rules.
- Verify Mercosur incorporation, regularisation, labelling and transition periods.
- Dokumentieren Sie die Quellenversion und prüfen Sie die Behörde vor Herstellung, Notifizierung oder Inverkehrbringen erneut.
In diesem Eintrag verfügbare Felder
- Amtlicher StoffnameVerfügbar
- CASVerfügbar
- ECVerfügbar
- Gesonderter BedingungstextVerfügbar
- Datum des InkrafttretensVerfügbar
- Snapshot-Hash und MethodeVerfügbar
Fragen, die diese Seite beantwortet
Dauerhafte Zitierweise
Dextrometorfano* e seus sais. RDC 529/2021 consolidated annex, entry 226 (through RDC 1.030/2026). Brazil. Source version RDC 529/2021 consolidated through RDC 1.030/2026. CosIng Checker regulatory record: https://cosingchecker.com/de/regulations/br/records/13432/
Zitieren Sie die Aufsichtsbehörde als rechtliche Autorität. Diese Seite ist ein strukturierter Belegindex und eine Verifizierungshilfe, kein Ersatz für den amtlichen Text oder eine fachkundige rechtliche Bewertung.
Auslegung und Grenzen für Brazil
This official record identifies the substance as prohibited for cosmetic use in the stated market scope.
Do not rely on a formulation containing this identity until the cited source, effective date and exact substance match have been verified.
Wie die Rechtsrolle auszulegen ist
The cited row forms part of a binding rule or legally incorporated list for this market.
Belege auf dieser Seite
- Erfasstes Ergebnis: Prohibited
- Rechtsrolle: Binding rule
- Quellenversion: RDC 529/2021 consolidated through RDC 1.030/2026
- Datum des Inkrafttretens: 2026-06-15
Was es nicht beweist
RDC 1.030/2026 amends rather than replaces the prohibited baseline, and the second restricted-list revision was still under consultation in July 2026.
Weitere maßgebliche Stoffrecherche
Keine dieser Quellen hebt die oben genannte Marktentscheidung auf.
Cosmetic Ingredient Review safety assessments
Expert Panel conclusions, assessed ingredient groups, use conditions, dates and report documents
Independent expert review considered by FDA; not a government approval or binding market rule
Diese Identität bei der Quelle recherchierenFDA Global Substance Registration System
UNII identifiers, preferred names, substance types, codes and public substance relationships
Identity registry only; UNII availability does not imply FDA review or approval
Diese Identität bei der Quelle recherchierenILO/WHO International Chemical Safety Cards
Hazards, symptoms, first aid, storage, incompatibilities and physical properties for covered chemicals
International occupational chemical-safety reference; not cosmetic-use approval
Diese Identität bei der Quelle recherchierenJapan NITE-CHRIP
Chemical identity, Japanese and foreign legal lists, GHS hazards and exposure-related information
Chemical-management evidence; cosmetic status remains governed by the applicable MHLW standard and market rules
Diese Identität bei der Quelle recherchierenNIOSH Pocket Guide to Chemical Hazards
REL, PEL, IDLH, properties, exposure routes, symptoms, target organs, first aid and measurement methods for covered workplace chemicals
US occupational-health guidance and limits; not a cosmetic ingredient decision
Diese Identität bei der Quelle recherchierenOECD eChemPortal
Gateway to authority-owned physical-property, fate, ecotoxicity, toxicity, exposure and GHS records
Discovery gateway; each linked authority remains responsible for its data
Diese Identität bei der Quelle recherchierenUS EPA CompTox CTX APIs
Für den Import ist ein API-Schlüssel erforderlichDTXSID identity, experimental and predicted properties, toxicity, bioactivity, exposure and environmental data
Scientific and computational evidence; predictions must remain labelled and do not determine cosmetic legality
Diese Identität bei der Quelle recherchieren